1. Introduction {#sec1}
===============

Parkinson\'s disease (PD) is the second most common neurodegenerative disease, which is characterized by static tremors, rigidity, bradykinesia, and postural instability. Widespread neuronal loss occurs in PD patients\' brain, especially the progressive degeneration of dopaminergic neurons in the substantia nigra compacta \[[@B1]\]. The surviving neurons present inclusion bodies (Lewis bodies) containing *α*-synuclein in the central and peripheral nervous systems \[[@B2]\]. Genetic factors contribute significantly to the complex pathogenesis of PD \[[@B3]\]. 10% patients with hereditary PD carry disease-causing mutations, while most patients with sporadic PD may carry single nucleotide polymorphisms \[[@B4]\]. Common PD-related mutant genes include the synuclein alpha (*SNCA*), leucine-rich repeat kinase 2 (*LRRK2*), PTEN-induced putative kinase 1 (*PINK1*), parkin RBR E3 ubiquitin protein ligase (*PARK2*), and cytoplasmic protein sorting 35 (*VPS35*). Among them, *SNCA*, *LRRK2*, and *VPS35* are associated with PD in autosomal dominant forms, and *PINK1* and *PARK2* are associated with PD in autosomal recessive forms. In addition, genome-wide association studies have found that plenty of variants in glucosidase beta acid (*GBA*) are risk factors for PD \[[@B5]\].

At the cellular level, the molecular mechanisms of PD involve oxidative stress, mitochondrial dysfunction, autophagy, axonal transport, and neuroinflammation \[[@B5]\]. Increased oxidative stress products can damage macromolecules and cause mitochondrial dysfunction, which subsequently triggers mitochondrial autophagy. These pathways converge in the accumulation and aggregation of alpha-synuclein, a marker of PD. And the PD-related mutant genes may play multiple roles in these pathways, which is complex and elusive.

The emergence of induced pluripotent stem cells (iPSCs) has greatly promoted the research process of PD molecular mechanism. IPSCs are cells that resemble embryonic stem cells by transferring OCT4, Sox2, Klf4, and c-Myc (Yamanaka factor) retroviruses to somatic cells \[[@B6], [@B7]\]. Reprogrammed iPSCs have multiple differentiation potentials and are capable of self-renewal, similar to embryonic stem cells. More importantly, iPSCs have a patient\'s complete genomic background, providing a platform to more directly investigate the impact of genetic mutations on disease occurrence. Park et al. were the first to successfully establish iPSC models from PD patients \[[@B8]\]. And Soldner et al. differentiated iPSCs into dopaminergic (DA) neurons for the first time \[[@B9]\]. Subsequently, more and more iPSC models were established and differentiated into neurons to simulate the phenotype of PD \[[@B10]\]. The CRISPR/Cas9 system, an RNA-based endonuclease, can add/delete or modify genomes in living cells. Based on iPSC models, the CRISPR-Cas9 system has been effectively used for many purposes, such as allele-specific genome-targeted knockout \[[@B11]\] and knock-in \[[@B12]\], regulation of endogenous gene expression \[[@B13], [@B14]\], and isogenic iPSC line correcting \[[@B15]\]. The establishment of iPSC models, CRISPR/Cas9 system, and directional differentiation into neurons jointly control pathogenic genes as a single variable and eliminate phenotypic differences caused by individual inheritance, providing a more direct understanding of the relationship between specific genes and PD.

In this review, we summarized the current work on iPSC models with mutations in *SNCA*, *LRRK2*, *PINK1/Park2*, *VPS35*, and *GBA*. And we described the potentials and challenges of the iPSC models and their future development prospects.

2. Synuclein Alpha (*SNCA*) {#sec2}
===========================

*SNCA* was the first gene found in familial PD, which encodes *α*-synuclein (a core pathological marker of PD) \[[@B16]\]. The pathogenic *SNCA* reported mainly include point mutations (p.A53T, p.A30P, p.E64K, p.H50Q, p.G51D, and p.A53E), duplication, and triplication \[[@B17], [@B18]\]. Mutations or replication of *SNCA* makes *α*-synuclein conformational changes or dose increase, which leads to the occurrence of PD. The triplicated *SNCA* was first discovered in 2003 in an American family with PD \[[@B19]\]. Devine et al. were the first to establish iPSCs carrying *SNCA* triple replication and differentiated iPSCs into midbrain dopaminergic (mDA) neurons. These iPSC-derived dopaminergic neurons successfully mimicked the PD phenotype of *α*-synuclein accumulation, which were not detected in the skin fibroblasts from PD patients \[[@B20]\]. *SNCA*-related iPSC models are mainly derived from patients carrying *SNCA* triple replication, as this kind of model simulates the typical manifestations of PD. The role of *α*-synuclein in DA neurons derived from SNCA triplication iPSCs is depicted in [Figure 1](#fig1){ref-type="fig"}.

2.1. Oxidative Stress {#sec2.1}
---------------------

The triplicated *SNCA* iPSC-derived DA neurons have a 2-fold increase in *α*-synuclein protein levels \[[@B20]\] and a 6-fold increase in mRNA levels \[[@B21]\]. The observed PD characterization of *SNCA* triplication iPSC-derived mDA neurons includes not only the accumulation of *α*-synuclein but also the intrinsic overexpression of oxidative stress markers and peroxide-induced oxidation \[[@B22]\]. Under environmental toxin or oxidative stress conditions, *SNCA* triplication iPSC-derived neural stem cells have higher vulnerability and increased oxidative stress sensitivity. Importantly, this phenotype can be reversed by knocking out endogenous *α*-synuclein \[[@B23]\]. Other studies have found that even small doses of *α*-synuclein are sufficient to induce large amounts of ROS. The resulting ROS, with free metal ion dependence, is induced by oligomers of *α*-synuclein rather than fibers \[[@B17]\]. Increased oxidative stress causes the imbalance of miRNAs in neurons \[[@B18]\], which is harmful to the nervous system \[[@B24]\]. Moreover, different oxidative stress signals produce different molecular effects in *SNCA* triple iPSC-derived DA neurons. Manganese results in a concentration- and time-dependent increase in intracellular ROS/nitrogen species, while rotenone causes an increase in intracellular lipid peroxidation (isoprostane) \[[@B25]\]. Remarkably, in *SNCA* triplication iPSC-derived cortical neurons, *α*-synuclein was found to induce endoplasmic reticulum stress by activating the unfolded protein response (UPR) of the IRE1*α*/XBP1 axis \[[@B26]\].

2.2. Nuclear Toxicity {#sec2.2}
---------------------

Under physiological conditions, a small amount of *α*-synuclein is localized in the nuclei of neuronal cells \[[@B27]\]. When subjected to oxidative stress, extranuclear *α*-synuclein is cleaved by the proteasomes. Large fragments remain in the cytoplasm to increase stress-induced cell death, and small fragments in the C-terminal region translocate from the cytoplasm to the nucleus \[[@B28], [@B29]\]. *In vitro* and *in vivo* experiments have shown that *α*-synuclein can bind to chromatin \[[@B28]\] and activate the DNA damage response \[[@B30]\]. Another recent study showed that misfolded *α*-synuclein breaks the genomic DNA strand by opening a DNA nick. This DNA damage can be synergistic with Fe ions, promoting the death of *SNCA* triplication iPSC-derived neural progenitor cells \[[@B31]\]. In addition, *α*-synuclein may induce neurotoxicity by accelerating the cell cycle \[[@B32]\]. One study used a "seminatural" approach that prolongs culture time to induce senescence. Neurons from patients with *SNCA* triplication iPSCs developed earlier and faster nuclear senescence phenotypes, including nuclear folding as well as increased nuclear markers hp1*γ* and h3k9me3 \[[@B31]\]. Therefore, *α*-synuclein may mediate nuclear toxicity by impairing genomic integrity and accelerating senescence in *SNCA* triplication iPSC-derived neuronal nuclei.

2.3. Mitochondrial Toxicity {#sec2.3}
---------------------------

A high-throughput analysis showed that *SNCA* triplication iPSC-induced DA neurons harbored mitochondrial morphological changes and a decrease in mitochondrial membrane potential \[[@B33]\]. A transcriptomic analysis of purified *SNCA* triplication iPSC-derived DA neurons revealed perturbation of gene expression associated with mitochondrial function. This is consistent with the observed mitochondrial damage phenotype \[[@B34]\]. Animal and *in vitro* experiments showed that pathogenic *β*-sheet-rich *α*-synuclein oligomers are preferentially localized to mitochondria than wild-type *α*-synuclein, and accumulated *α*-synuclein deposits mediate mitochondrial dysfunction \[[@B35]\]. In *SNCA* triplication iPSC-derived DA neurons, *α*-synuclein (1) induces ATP synthase *β* subunit and mitochondrial lipid binding, opening osmotic conversion pores \[[@B36]\]; (2) binds to the endoplasmic reticulum-mitochondrial binding protein VAPB, disrupting the VAPB-PTPIP51 chain to relax the endoplasmic reticulum-mitochondrial association, Ca^2+^ homeostasis, and mitochondrial ATP production \[[@B37]\]; and (3) binds to the exposed cardiolipin on the mitochondrial outer membrane and increases the exposure time of the cardiolipin. Prolonged exposure of cardiolipin promotes refolding of the *α*-synthetic fibers and initiates recruitment of LC3 to mitochondria and mitochondrial autophagy \[[@B38]\]. Overexpression of ATP-dependent CLP protease reduces *α*-synuclein-induced mitochondrial oxidative stress, inhibits *α*-synuclein s129 phosphorylation accumulation, and promotes neuronal morphology by increasing the restoration of superoxide dismutase-2 levels \[[@B39]\].

2.4. Lysosomal Dysfunction {#sec2.4}
--------------------------

Aggregated *α*-synuclein enhances autophagy activity to meet the needs of its degradation \[[@B40]\], while excessive *α*-synuclein can mediate the pathological manifestations of lysosomes \[[@B41]\]. Glucocerebrosidase and *α*-synuclein form a two-way pathogenic loop in synucleinopathy \[[@B42]\]. A study showed that in *SNCA* triplication iPSC-derived mDA neurons, accumulated *α*-synuclein disrupts RAB1a-mediated hydrolase transport and reduces lysosomal function through an abnormal association with the cis-Golgi-binding factor GM130. Overexpression of RAB1a restores the Golgi structure, improves hydrolase transport and activity, and reduces pathological *α*-synuclein in patient neurons \[[@B43]\]. Consistent with these findings, another study showed that in *SNCA* triplication iPSC-derived DA neurons, *α*-synuclein is reduced by a noninhibitory small molecule of *β*-glucocerebrosidase (GCase), which is sufficient to reverse the downstream cytopathies, including hydrolase maturation and perturbation of lysosomal dysfunction \[[@B44]\]. In addition, *SNCA* triplication causes excess *α*-synuclein to impair phagocytosis in iPSC-derived macrophages. And iPSC-derived macrophages stop the degradation of *α*-synuclein by blocking lysosome and proteasome paths \[[@B45]\].

2.5. Axon Dysfunction {#sec2.5}
---------------------

Axon transport relies on microtubules and motor proteins (kinesins and dynein), which is the basis for maintaining neuronal homeostasis \[[@B46]\]. Animal studies have shown that synucleinopathy begins at the synaptic terminals \[[@B47]--[@B49]\]. Mild overexpression of the mutant *α*-synuclein oligomers significantly reduces microtubule stability and impairs neurite network morphology \[[@B50]\]. A further study confirmed that the acidic C-terminal region of the toxic *α*-synuclein fibrils interacted with the basic central region of Tau, interfering with Tau-promoted microtubule assembly \[[@B51], [@B52]\]. In *SNCA* triplication iPSCs, oligomers of *α*-synuclein are relocated using the transport regulatory proteins Miro1, KLC1, and Tau, affecting mitochondrial anterograde axonal transport. Moreover, the presence of high levels of *α*-synuclein leads to decreased axonal density and structural synaptic degradation of iPSC-derived neurons \[[@B53]\].

3. Leucine-Rich Repeat Kinase 2 (LRRK2) {#sec3}
=======================================

LRRK2 is a protein with dual enzyme functions (GTPase and serine threonine kinase), which exists in the form of dimerization and binds to various organelle membranes to regulate the cytoskeleton \[[@B54]\]. LRRK2 participates in autophagy, immunity, and other physiological functions. The *LRRK2* G2019S mutation has the effect of enhancing LRRK2 kinase activity, and the first *LRRK2* iPSCs were established in 2012 \[[@B55]\]. Hereafter, *LRRK2* iPSC models carrying mutations G2385R \[[@B56]\], R1628P \[[@B57]\], N551K \[[@B58]\], and S1647T \[[@B59]\] were also established. The role of LRRK2 in iPSC-derived neurons is depicted in [Figure 2](#fig2){ref-type="fig"}.

3.1. Protein Homeostasis {#sec3.1}
------------------------

LRRK2 interacts with *α*-synuclein. Increased *α*-synuclein level was found in *LRRK2* G2019S iPSC-derived neurons \[[@B60]\]. A study showed that LRRK2 could be able to modify *α*-synuclein pathology, and the presence of *LRRK2* G2019S enhanced the accumulation of endogenous *α*-synuclein in a time-dependent manner, accelerating neuronal degeneration, while *LRRK2* deletion reduced aggregation \[[@B61]\]. In human neurons derived from *LRRK2* G2019S iPSCs, *LRRK2* G2019S rapidly internalized recombinant human preformed-fibril, triggering the accumulation of endogenously expressed *α*-synuclein. This demonstrates that LRRK2 G2019S increases the formation of *α*-synuclein aggregates in patient neurons derived from iPSCs \[[@B61]\]. Furthermore, Daher showed that LRRK2 inhibitors can reduce neurodegeneration associated with abnormal *α*-synuclein accumulation \[[@B62]\].

3.2. Neuronal Differentiation {#sec3.2}
-----------------------------

*LRRK2* mutations affect the ability of neurons to differentiate. Liu et al. found that iPSC-derived neural stem cells of *LRRK2* G2019S showed a passage-dependent defect in clonal expansion and neuronal differentiation \[[@B55]\]. In another study conducted by Bahnassawy et al., *LRRK2* R1441C neural stem cells were found to have impaired neuronal differentiation phenotypes, and *LRRK2* R1441C-deficient neural stem cells differentiated faster than wild-type cells \[[@B63]\]. Borgs et al. also demonstrated that *LRRK2* G2019S iPSCs are inefficient in the process of differentiation into DA neurons \[[@B64]\]. Further research on the specific role LRRK2 plays in neuronal differentiation is needed.

3.3. Neuronal Growth and Development {#sec3.3}
------------------------------------

LRRK2 plays a role in neurite elongation and dendritization. The iPSC-derived sensory neurons of the *LRRK2* G2019S showed shortened neurites, reduced neurite outgrowth, microtubule-rich axon aggregation, and altered calcium dynamics. Treatment with LRRK2 kinase inhibitors can rescue this phenotype \[[@B65]\]. Borgs et al. reported significant branching defects in *LRRK2* G2019S iPSC-derived DA neurons \[[@B64]\]. Qing et al. found that in the *LRRK2* G2019S iPSC-derived mDA neurons, the percentage of TH-positive neurons with a total axon length greater than 2,000 *μ*m decreased significantly and the average branch of DA neurons decreased \[[@B12]\]. In addition, Korecka et al. recently confirmed that *LRRK2* G2019S can cause neuronal calcium-dependent phenotypic dysplasia. The *LRRK2* G2019S iPSC-derived mDA neurons had lower baseline ER-Ca^2+^ levels, while Ca^2+^ influx increased and Ca^2+^ buffering capacity decreased after membrane depolarization. After inhibiting the action of ER-Ca^2+^-ATPase, the *LRRK2* G2019S iPSC-derived neurons showed a neurite collapse phenotype \[[@B66]\].

3.4. Mitochondrial Dysfunction {#sec3.4}
------------------------------

About 10% of dimerized LRRK2 proteins are localized to the mitochondria and interact with substances on the mitochondrial membrane. Mutations in *LRRK2* G2019S can cause aberrations of mitochondrial morphology and function, an increase in mitochondrial number and mitochondrial debris, a decrease in mitochondrial membrane potential. This mitochondrial defect was found in the *LRRK2* G2019S iPSC-derived neuroepithelial stem cells in Walter\'s study \[[@B67]\]. Pathogenic LRRK2 mutations can induce mitochondrial genome damage and mitochondrial transport-related PD pathogenesis \[[@B68]\]. In Sanders et al.\'s study, iPSC-derived DA neurons carrying the *LRRK2* G2019S or R1441C mutation showed high mitochondrial DNA (mtDNA) levels in iPSCs neurons when compared to normal iPSC-derived neurons. However, no mtDNA damage was found in iPSC-derived DA neurons, which were repaired by zinc finger nucleases \[[@B68]\]. Subsequently, another study confirmed that the mutated LRRK2 impairs mtDNA in a kinase-dependent manner. Inhibition of LRRK2 kinase activity can block or reverse mtDNA damage \[[@B69]\]. Notably, LRRK2 affects mitochondrial transport and impairs mitochondrial clearance. Under normal physiological conditions, LRRK2 forms a complex with the external mitochondrial membrane protein Miro. It promotes Miro removal and links PINK1 and parkin to Miro. Pathogenic *LRRK2* G2019S disrupts this pathway, arresting the movement of damaged mitochondria along the cytoskeleton and delaying mitochondrial autophagy \[[@B70]\]. Another study also confirmed mitochondrial distribution and trafficking abnormalities in LRRK2 mutant neurons, accompanied by significantly low endogenous NAD+ levels and decreased protein lysine deacetylase activity, leading to bioenergy defects \[[@B71]\].

3.5. Synaptic Vesicle Transport {#sec3.5}
-------------------------------

The serine/threonine kinase activity of LRRK2 is important in the endocytosis of synaptic vesicles. *LRRK2* G2019S selectively impairs the endocytosis of synaptic vesicles in iPSC-derived ventral midbrain neurons (including DA neurons). Inhibition of LRRK2 kinase activity can rescue slow endocytosis. Through transcriptomics and proteomics analyses, Connor-Robson et al. found that *LRRK2* G2019S iPSC-derived DA neurons had a high degree of dysregulation of the inner circulation pathway \[[@B72]\]. The results revealed that a variety of key endocytic proteins were downregulated in cultures of *LRRK2* R1441C iPSC-derived DA neurons, such as endothelial cytokines I-III, dynamin-1, and various Rab proteins. Their study confirmed that clathrin-mediated endocytosis was disrupted \[[@B73]\]. Recently, Nguyen and Krainc reported that LRRK2 interacted with auxilin to jointly damage clathrin-mediated endocytosis of synaptic vesicles. They found auxin, which is phosphorylated by LRRK2, interfered with clathrin, resulting in disruption of synaptic vesicle endocytosis and decreased synaptic vesicle density in *LRRK2* iPSC-derived DA neurons \[[@B74]\]. LRRK2-mediated impaired synaptic vesicle endocytosis contributes to the accumulation of oxidized dopamine, producing dopamine-mediated toxic effects in iPSC-derived DA neurons, such as reduced glucocerebrosidase activity.

3.6. Autophagy {#sec3.6}
--------------

Normally, LRRK2 is degraded by proteasome and lysosomal pathways. The chaperone-mediated autophagy (CMA) pathway promotes lysosomal degradation of LRRK2. *LRRK2* G2019S was found to be involved in increased accumulation and release of *α*-synuclein \[[@B75]\]. *LRRK2* G2019S iPSC-derived mDA neurons showed higher levels of LC3 II than normal control cell lines, which represented the basal level of autophagy. This is possibly due to abnormal autophagosome clearance. Surprisingly, the phenotype of abnormal autophagy and neuronal damage in *LRRK2* G2019S iPSC-derived DA neurons can be rescued by the fission dynamin-related protein 1 (DRP1) peptide inhibitor p110 \[[@B76]\]. This suggests that mitochondrial hypermutation is involved in autophagy-associated PD mechanisms. In addition, leucine-tRNA synthetase (LRS) ligates leucine to tRNA Leu and activates rapamycin complex 1 (mTORC1). Ho et al. demonstrated that downregulation of LRS can enhance autophagy. LRRK2 phosphorylated LRS levels in the DA neurons of *LRRK2* G2019S, and LRS phosphorylation impaired autophagy through protein folding errors and endoplasmic reticulum stress mediated by LRS editing defects \[[@B77]\].

3.7. Neuroimmune Inflammation {#sec3.7}
-----------------------------

In recent years, LRRK2 was found to be involved in the immune pathway of PD in both the central and peripheral systems, including innate immunity and acquired immunity \[[@B78]\]. LRRK2 is highly expressed in immune cells such as macrophages and microglia. Lopez de Maturana et al. found that *LRRK2* mutations affect *α*-synuclein regulation and impair NF-*κ*B classical signaling. LRRK2 silencing reduced *α*-synuclein levels in mutant neurons and NF-*κ*B dysregulation in mutant neurons. Moreover, NF-*κ*B dysregulation was found in mutant neurons \[[@B79]\]. In addition, Booth et al. found that matrix metalloproteinase 2 (mmp2) and transforming growth factor *β*1 (TGF*β*1) were downregulated in the cytoplasm of *LRRK2* G2019S iPSC-derived astrocytes, suggesting that *LRRK2* G2019S mutation may interfere with astrocytes \[[@B80]\]. Furthermore, *LRRK2* mutation resulted in accelerated production of *LRRK2* iPSC-derived monocytes and a decrease in noncanonical CD14^+^CD16^+^ monocyte subsets. The migration ability of these monocytes was found to be impaired. These results indicate that LRRK2 also plays a key role in hematopoiesis, supporting the pathogenic role of immunity in PD \[[@B81]\].

4. PTEN-Induced Kinase 1 (*PINK1*) and Parkin RBR E3 Ubiquitin Protein Ligase (*PARK2*) {#sec4}
=======================================================================================

PTEN-induced kinase 1 (*PINK1*) is a mitochondrial serine/threonine-protein kinase encoded by the *PINK1* gene. It is involved in the regulation of mitochondrial degradation and protects cells from stress. Parkin, produced by the *PARK2* gene, is involved in the maintenance of mitochondrial function and integrity. The role of PINK1 and parkin in iPSC-derived neurons is depicted in [Figure 3](#fig3){ref-type="fig"}.

4.1. Oxidative Stress {#sec4.1}
---------------------

Initial studies have shown that PINK1 deficiency caused embryonic stem cell-derived dopaminergic neurons to exhibit significant oxidative stress characteristics, as these neurons died through the mitochondrial apoptotic pathway \[[@B82]\]. This phenotype was observed in the *PINK1* iPSC-derived neural cell population. Imaizumi et al. conducted a study of *PARK2* iPSC-derived neuron, observing the similar phenotypes with increased levels of oxidative stress. In addition, the Nrf2 pathway was activated in *PARK2* iPSC-derived neurons \[[@B83]\]. Another study showed a higher susceptibility to rotenone-induced mitochondrial stress in *PARK2* iPSC-derived DA neurons. This phenotype can be prevented by T-type calcium channel inhibition or antagonists. These studies have demonstrated the induction of oxidative stress in neurons by PINK1 and parkin \[[@B84]\].

4.2. Mitochondrial Dysfunction {#sec4.2}
------------------------------

IPSC-derived mDA neurons carrying *PINK1* and *PARK2* mutations showed PD pathology of mitochondrial dysfunction \[[@B85]\]. Cooper et al. observed elevated ROS, decreased mitochondrial respiration, proton leakage, and impaired mitochondrial movement in *PINK1* iPSC-derived neurons \[[@B86]\]. Seibler et al. found that in the presence of mutant *PINK1*, the mtDNA copy number increased and upregulation of PGC-1*α* in iPSC-derived DA neurons occurred, implying that PINK1 impaired mitochondrial function due to loss of function \[[@B87]\]. In Vos et al.\'s study, the fatty acid synthase (Fasn) activity of *PINK1* iPSC-derived DA neurons decreased, resulting in decreased palmitate levels and increased cardiolipin (CL) levels. Importantly, increased cardiolipin can promote electron transfer between ubiquinone and complex I to rescue PINK1 deficiency \[[@B88]\].

Parkin also plays an important role in the mitochondria. *PARK2* iPSC-derived mDA neurons also exhibited mitochondrial dysfunction, abnormal mitochondrial morphology, decreased mitochondrial volume fraction, and impaired mitochondrial homeostasis. But these phenotypes were not observed in dermal fibroblasts and iPSCs \[[@B89]\]. This neuron-specific mitochondrial-damaged phenotype is consistent with that of previous studies \[[@B83]\]. Recent studies showed that parkin interacted with Stomatin-like protein 2 (SLP-2), which binds to mitochondria and functions in the assembly of the respiratory chain protein. Loss of parkin results in decreased complex I activity and increased mitochondrial fragmentation, whereas the overexpression of SLP-2 could rescue these phenotypes \[[@B90], [@B91]\]. It is worth noting that the *PARK2* mutation was found to affect the cellular energy metabolism rhythm. A recent study performed by Pacelli et al. has shown that iPSCs carrying the *PARK2* mutation and its differentiated neural stem cells were observed to be severely damped in the bioenergy oscillation mode \[[@B92]\].

4.3. Mitochondrial Autophagy {#sec4.3}
----------------------------

PINK1 initiates ubiquitin-mediated mitochondrial autophagy via parkin \[[@B93]\]. When the mitochondrial membrane potential is lost, PINK1 is degraded by the proteasome and accumulates on the damaged mitochondria while parkin is transported to the mitochondria in a PINK1-dependent manner, ubiquitinating the mitochondrial outer membrane protein (more of a large molecular weight protein) \[[@B94], [@B95]\]. Damaged mitochondria are labeled with polyubiquitin phosphorylation and cleared by mitochondrial autophagy to protect the neurons. A study showed that in *PINK1* iPSCs, both endogenous parkin and overexpressing parkin were insufficient to induce mitochondrial autophagy following the loss of mitochondrial membrane potential \[[@B94]\]. Another study found that in *PINK1* iPSC-derived DA neurons, mitochondrial recruitment was impaired under stress conditions, even overexpressing parkin. But the expression of wild-type PINK1 can rescue parkin-localized impaired mitochondrial dysfunction \[[@B87]\]. These two studies showed the important role of PINK1 in mitochondrial autophagy. Moreover, Oh et al. found that the S-nitrosylation of the Cys568 site of PINK1 downregulates its kinase activity, and S-nitrosylated PINK1 reduces parkin translocation to the mitochondrial membrane, disrupting iPSC-derived neuronal mitochondrial autophagy \[[@B96]\]. In addition, mitochondrial autophagy was also observed to be impaired in the iPSC-derived DA neurons of the *PARK2* mutation \[[@B97]\]. This signifies the importance of PINK1 and parkin in the mitochondrial autophagy pathway.

4.4. Dopamine Regulation {#sec4.4}
------------------------

Another important function of parkin is to regulate dopamine in neurons. High levels of dopamine in the cytoplasm can lead to an increase in metabolites toxic to neurons, such as 6-hydroxydopamine \[[@B78]\]. *PARK2* iPSC-derived DA neurons showed decreased dopamine uptake and increased spontaneous dopamine release. So, parkin was presumed to control dopamine utilization in human mDA neurons by increasing the accuracy of dopamine neurotransmission and inhibiting dopamine oxidation \[[@B98]\]. A recent study has found that activation of dopamine D1 receptors in *PARK2* iPSC-derived midbrain neurons causes large rhythmic outbreaks of spontaneous excitatory postsynaptic currents (EPSCs) \[[@B99]\]. Importantly, Zhong et al. found that parkin\'s overexpression, but not its PD-causing mutant, abolished the oscillatory activity of the patient\'s neurons. These results indicate that *PARK2* mutations significantly enhance the regulation of abnormal dopaminergic regulation of presynaptic glutamate transmission in midbrain neurons \[[@B99]\].

4.5. Microtubule System {#sec4.5}
-----------------------

Microtubules transport the organelles necessary for outgrowth under normal physiological conditions. Previous studies have demonstrated that parkin bonds to microtubules with high affinity \[[@B100], [@B101]\] and stabilizes microtubules against toxicity \[[@B102]\]. Ren et al. found that the *PARK2* iPSC DA neurons significantly reduced complexity \[[@B103]\]. They used the microtubule depolymerizing agent colchicine to mimic the role of *PARK2* mutations by reducing the length and complexity of the control neuronal neurites, while the microtubule-stabilizing drug paclitaxel mimics the role of parkin overexpression by enhancing the morphology of parkin-deficient neurons. These results indicated that parkin maintained the morphological complexity of human neurons by stabilizing the microtubules. Another study conducted by Cartelli et al. reported that parkin defects caused stable microtubule fragmentation and accelerated acetylation in *PARK2*-mutated iPSC neurons \[[@B104]\]. These studies confirmed that parkin plays a regulatory role in the microtubule system during neuronal aging.

5. VPS35 Retromer Complex Component (*VPS35*) {#sec5}
=============================================

*VPS35* encodes vacuolar protein sorting 35, which is a core component of the reversal complex. VPS35 localizes to dendritic spines and is involved in the recycling of proteins from the endosomes/lysosomes to the trans-Golgi network as well as from the endosomes to the plasma membrane \[[@B105]\]. The first two independent studies identified *VPS35* c.1858G\>A (p.Asp620Asn) in the hereditary PD family in Switzerland \[[@B106]\] and the Austrian PD family \[[@B107]\]. Subsequently, mutations such as c.1570C\>T (p.Arg524Trp) and c.946C\>T (p.Pro316Ser) were also reported. Munsie et al. first established a dopamine neuron model with iPSCs sourced from patients with *VPS35* p.D620N. They found this loss-of-function mutation altered the transport of the episome-dependent neurotransmitter receptor to the synapse. This disturbance of synaptic function may place chronic pathophysiological stress on the neuronal circuit \[[@B108]\]. Currently, there are few studies on the iPSC model based on *VPS35*. So it is necessary to further study the pathogenic mechanism of *VPS35* in the iPSC models.

6. Glucosidase Beta Acid (*GBA*) {#sec6}
================================

*GBA* encodes a hemolytic hydrolase *β*-glucocerebrosidase (GCase). GCase degrades glucosylceramide (GluCer) to glucose and ceramide in lysosomes. The *GBA* mutation is the strongest risk gene for PD \[[@B109]\]. Common *GBA* mutations are N370S and L444P. Woodard et al. first established *GBA* iPSC-derived DA cells from single-oval twins carrying with the *GBA* N370S mutation \[[@B110]\]. The role of GBA in iPSC-derived neurons is depicted in [Figure 4](#fig4){ref-type="fig"}.

6.1. Protein Homeostasis {#sec6.1}
------------------------

Woodard et al. found that GBA enzyme activity was lower and *α*-synuclein levels were significantly elevated \[[@B110]\]. Another independent study demonstrated that in *GBA* iPSC-derived DA neurons, *GBA* mutations resulted in decreased glycosidase activity and storage of glycolipid substrates \[[@B111]\]. Correspondingly, *α*-synuclein aggregation occurs in iPSC-derived mDA neurons exposed to GCase inhibitors. Kim et al.\'s study has shown that the lack of GCase reduces the aggregation of physiologically formed *α*-synuclein tetramers and increase the presence of *α*-synuclein monomers, leading to neurotoxicity. Importantly, overexpression of GCase reverses this process \[[@B112]\]. In addition, glucosyl sphingosine (GlcSph) and sphingosine (Sph), members of the lipid family of ceramides, potently promoted the accumulation of pathological *α*-synuclein in *GBA* iPSC-derived neurons \[[@B113]\]. A study has shown that mutated GBA reduces the function of GCase and increases the accumulation of *α*-synuclein, which may be possible through the autophagolysosomal pathway that disrupts *α*-synuclein \[[@B114]\]. The increased aggregation of *α*-synuclein feedback inhibits the activity of glucocerebrosidase, and this bidirectional circulation leads to the development of *GBA*-associated PD.

6.2. Pathological Mechanism of PD Mediated by GBA Mutation {#sec6.2}
----------------------------------------------------------

In iPSC-derived DA neurons carrying the *GBA*-N370S mutation, *GBA* mutation disrupted the physiological structure of GCase in the endoplasmic reticulum, activated the unfolded protein response (UPR), and upregulated endoplasmic reticulum stress. In addition, the reduced activity of GCase impairs autophagy/lysosomal system function and expands the lysosomal compartment, making dopamine neurons susceptible to individual recognition. No increase in *α*-synuclein levels was observed in neurons of iPSC-derived DA neurons that were not mutated in *GBA*-N370S, but increased levels of extracellular *α*-synuclein release in culture \[[@B114]\]. Another study also reported that the *GBA* iPSC-derived mDA neurons were damaged by the autophagy system. It is worth noting that *GBA* mutant neurons also showed dysregulation of calcium homeostasis and increased susceptibility to calcium-induced stress responses \[[@B115]\]. Importantly, reduced levels of DA transporter and VMAT2 expression are shown in PD neurons, which may help reduce DA absorption in these cells \[[@B111]\]. In addition, GlcCer and GlcSph accumulation has been detected in *GBA*-KO iPSCs neuron mitochondria \[[@B116]\]. In *SNCA* iPSC-derived neurons, GlcCer levels and decreased ceramide levels were found to be elevated \[[@B43]\]. In conclusion, mutated *GBA* may induce neuronal PD phenotype through endoplasmic reticulum stress, autophagy/lysosomal dysfunction, and calcium homeostasis.

7. iPSC Models Confirm the Neuron-to-Neuron Transmission of *α*-Synuclein {#sec7}
=========================================================================

*α*-Synuclein, a key factor triggering PD, multiplies between cells in a prion-like manner, whose protein aggregates bind heparan sulfate proteoglycans (HSPGs) on the cell surface to transmit pathologic processes \[[@B117]\]. The exogenous *α*-synuclein fibrils are assembled with heparan sulfate proteoglycan \[[@B118]\] as well as membrane proteins on the cell surface. These fibrils are taken up by intracellular endocytosis and participate in intracellular direct and retrograde transport \[[@B119]\]. Exogenous *α*-synuclein acts as a template to promote endogenous *α*-synuclein from a physiological *α* helix to an insoluble beta-fold conformation, aggregating protease K-resistant oligomeric fibrils. This pathogenic process exists not only between neuronal cells but also within the brain regions where the nervous systems are interconnected.

The theory of iPSC-derived human neuron models confirms the spread of *α*-synuclein between neurons. Yamasaki et al. demonstrated the propagating seed characteristics of *α*-synuclein insoluble monomers \[[@B120], [@B121]\]. Gribaudo et al. established a network of healthy human neurons in a cortical neuron network of microfluidic devices to find that *α*-synuclein multiplies between neurons in a dose- and structure-dependent manner, triggering PD-like pathology \[[@B122]\]. In addition, Surguchev et al. showed that extracellular *α*-synuclein interacts with cell membrane receptors such as cytoplasmic protein, lymphocyte activating gene 3, and Toll-like receptor 2. Cell signaling promotes *α*-synuclein to propagate between different cells \[[@B123]\]. The above results together indicate that in the neurons of patients with familial Parkinson\'s disease caused by genetic mutations, their *α*-synuclein pathology has sufficient seed characteristics to cause age-dependent human neuronal degeneration spread in brains.

8. The Potentials and Challenges of iPSC Technology {#sec8}
===================================================

Considering the insertion of oncogenes c-Myc and Klf4 increases the risk of mutation and transformation into cancer cells, subsequent studies have made various improvements in reprogramming methods. Soldner et al. used Cre recombinase after reprogramming to remove viruses and successfully obtained factor-free iPSCs that are more closely related to human embryonic stem cells \[[@B9]\]. Other researches performed more effective reprogramming procedure using safer vectors, such as nonintegrated vectors \[[@B124]--[@B126]\], synthetically modified mRNAs \[[@B127]--[@B129]\], cell membrane permeable proteins \[[@B130], [@B131]\], and small molecule compounds \[[@B132]--[@B134]\]. These technologies maximize genomic integrity and reduce the risk of transformation to cancer.

Genome-wide association analysis, sequencing of whole exomes and transcriptomes, has revealed an increasing number of disease genomics and proteomics, which greatly facilitates the study of neurodegenerative diseases \[[@B135]\]. In single-gene diseases, iPSCs that faithfully mimic disease phenotypes validate newly proposed disease mechanisms \[[@B136]\] and screen for therapeutic factors \[[@B137]\]. In polygenic diseases, iPSC library can be used to analyze the effects of SNPs and drug response differences \[[@B138]\]. iPSC technology and gene editing systems obtaining and target-editing of individual genome are potential strategies with great personalized treatment.

Dopamine supplementation and surgery are the first line of clinical treatment of PD to slow the progression of the disease \[[@B1]\]. Transplanted fetal midbrain cells were initially used in an attempt to treat poor endogenous nerve repair in patients with PD \[[@B139]--[@B141]\]. However, this technique has unavoidable limitations such as the uneven production of embryonic tissue and the susceptibility to genomic DNA damage during processing \[[@B141]\]. IPSCs have the advantages of avoiding genomic damage, enabling patients to adapt to HLA, high uniformity of cell grafts, and high proportion of dopaminergic neurons, which is also an ideal cell replacement therapy \[[@B127], [@B142]\]. In addition, cell-sorting techniques have been developed to reduce posttransplantation cancer risk, which target against the cell marker CORIN \[[@B143]\], the central nervous system microvascular endothelial marker LRTM1 \[[@B144]\], and activated leukocyte adhesion molecule (ALCAM) antibodies \[[@B145]\]. These cell-sorting technologies maintain the quality of transplanted cells and improve the safety and effectiveness of cell replacement therapy. Multiple animal trials have shown that iPSC transplantation is successful and safe in treating neurological diseases \[[@B146]--[@B148]\], and human clinical trials of Parkinson\'s disease using iPSCs are ongoing and observed \[[@B149]--[@B151]\]. Therefore, the iPSC treatment is expected to become a promising method for PD patients. In the near future, the clinical results of using iPSCs to treat Parkinson\'s disease are worth looking forward to.

Since the nervous system is not a single neuron but a complex culture system, the use of relatively simple 2D neurons in the disk modeling has not been able to meet the further need to explore PD. Various methods of cultivating 3D neural organs have been explored, such as Spin*Ω*\'s microrotating bioreactors to build brain organs (forebrain, midbrain, and hypothalamus) \[[@B152]\], the SFEBq method to produce the "cerebellum" \[[@B153]\], and the production of human cortical spheres \[[@B154]\]. Recently, the method of cultivating 3D organs using neural rosettes established by dual signals of SMAD and FGF has greatly enhanced the reproducibility of brain organoids \[[@B155]\]. These 3D models based on iPSC-derived neurons will help people to more stereoscopically understand the occurrence and progression of PD.

PD is age-dependent and often occurs as a patient age. While the iPSC derivative is young and its culture period is short. Studies have reported that the length of the telomerase of iPSCs greatly increased during the reprogramming process \[[@B156], [@B157]\]. In addition, reprogrammed stem cells also rearrange the mitochondrial network and a lower oxidative stress phenotype \[[@B158]\]. This reflects that the younger performance of iPSCs is different from the phenotype of aging cells. Research groups have been building iPSC models that express aging markers, such as progerin \[[@B159]\] and astrocytes \[[@B160]\]. Currently, it is a challenge to simulate age-growth neurons and to more closely integrate aging systems with PD.

9. Conclusions {#sec9}
==============

IPSCs offer a new platform for modeling and studying PD. While improvements still need to be made in iPSC-based disease modeling, this technology offers an unprecedented ability to mimic disease *in vitro* with patient-specific disease-relevant cell types. Human iPSC technology provides a more predictive platform for preclinical studies and improves the success of clinical trials, with the potential to deepen our understanding of the pathogenesis of disease.
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![The role of *α*-synuclein in mDA neurons derived from SNCA triplication iPSCs: (1) hydrolyzed by proteases into large fragments and small fragments of 10 kDa. Large fragments increase ROS levels. Small fragments enter the nucleus and induce nuclear DNA damage and nuclear senescence. (2) Localizes to Miro1, KLC1, and Tau to impair mitochondrial axonal transport. (3) Interacts with GCase to promote lysosomal dysfunction. (4) Participates in IRE1/XBP1 axis to increase endoplasmic reticulum oxidative stress. (5) Promotes lipid and ATP*β* subunit binding to open mitochondrial pores. (6) Combines with cardiolipin to increase cardiolipin exposure at mitochondrial surface. (7) Interferes with VAPB-PTPIP51 chain to affect mitochondrial calcium and ATP balance.](SCI2020-1061470.001){#fig1}

![The role of mutant LRRK2 in iPSC-derived DA neurons. Mutant LRRK2 (1) promotes aggregation of *α*-synuclein, (2) interferes with the transport of axonal vesicles, (3) disrupts Miro-induced mitochondrial transport, (4) increases mitochondrial DNA levels, (5) interferes with neuronal differentiation, (6) interferes with neuronal growth and development, (7) increases lysosomal autophagy, and (8) regulates the immune function of macrophages and astrocytes.](SCI2020-1061470.002){#fig2}

![The roles of the mutant PINK1 and parkin in iPSC-derived DA neurons. Mutant PARK2 (1) impairs recruitment to PINK1, (2) reduces dopamine vesicle endocytosis, (3) disrupts microtubule stability, (4) reduces neuron complexity, (5) increases neuronal spontaneous excitatory postsynaptic currents, and (6) increases dopamine release. Mutant PINK1 (7) elevates mitochondrial DNA levels, (8) increases mitochondrial oxidative stress, (9) increases autophagy, (10) decreases mitochondrial respiration, and (11) interferes with ubiquitin-mediated mitochondrial autophagy and lysosomal autophagy.](SCI2020-1061470.003){#fig3}

![The role of mutated GBA in iPSC-derived DA neurons. Mutant GBA (1) reduces GCase activity in lysosome and increases glycolipid substrate storage leading to lysosomal dysfunction; (2) disrupts calcium balance between mitochondria and lysosomes; (3) changes mitochondrial morphology, reduces mitochondrial respiration, and increases oxidative stress in mitochondria; (4) disrupts calcium balance between endoplasmic reticulum and mitochondria; (5) destroys GCase in endoplasmic reticulum to increase oxidative stress in endoplasmic reticulum; (6) disrupts intracellular sphingolipid homeostasis; (7) increases autophagy; and (8) reduces DA transporter and VMAT2 levels to interfere with dopamine uptake. Lysosomal dysfunction reduces *α*-synuclein monomers and accumulates *α*-synuclein tetramers.](SCI2020-1061470.004){#fig4}

[^1]: Academic Editor: Sarnowska Anna
